P3 HEALTH PARTNERS INC SEC Filings

P3 Health Partners Inc. reported continued operating losses and liquidity strain while scaling its Medicare Advantage-focused platform. The company recorded net losses of $43.7 million and $87.9 million for the three- and six-month periods ended June 30, 2025, respectively, and had $38.6 million of unrestricted cash as of June 30, 2025. A working capital deficit of $348.5 million and management's conclusion that substantial doubt exists about continuing as a going concern within one year were disclosed. The Company serves approximately 114,100 at-risk members through ~2,800 PCPs across 24 markets and relies on capitated per-member-per-month revenue. The filing describes related-party promissory financings (VGS 4 and VGS 5) carrying 19.5% annual interest with draw tranches and warrants, notes a 1-for-50 reverse stock split effective April 11, 2025, and discloses a DOJ civil investigative demand regarding broker arrangements.

P3 Health Partners Inc. director Gregory N. Kazarian was granted 2,000 restricted stock units (RSUs) on 08/06/2025, reported on a Form 4. Each RSU represents a right to receive one share of Class A common stock under the company’s 2021 Incentive Award Plan and the RSUs vest one year from the grant date. The award is reported with a $0 price as an equity grant and is coded as an acquisition.

After the grant Mr. Kazarian is reported to directly beneficially own 218,561 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 08/08/2025. No derivative securities are reported in Table II of the filing.

Mary A. Tolan, a director of P3 Health Partners Inc., was granted 2,000 restricted stock units (RSUs) under the company 2021 Incentive Award Plan on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the awards vest one year from the grant date. The grant was recorded with a reported price of $0. After the issuance, Ms. Tolan beneficially owns 218,561 shares of Class A common stock in a direct ownership form. The transaction was reported on a Form 4 as an acquisition by a reporting person who is a director.

P3 Health Partners reported that director Mark Thierer was granted 4,000 restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan, with the award recorded on 08/06/2025. Each RSU represents the right to receive one share of Class A common stock and the RSUs vest in one year from the grant date, meaning the shares will be issued if the vesting conditions are met. The filing shows the RSUs were issued at no cash price and increased Thierer’s reported beneficial ownership to 437,121 shares, held directly. No derivative securities were reported in this filing.

P3 Health Partners Inc. director Gregory D. Wasson received a grant of 2,000 restricted stock units (RSUs) on 08/06/2025 reported on a Form 4. The RSUs were granted under the 2021 Incentive Award Plan and each RSU represents the right to receive one share of Class A common stock. The award carries a $0 price and vests one year from the grant date. Following the reported transaction, Mr. Wasson is shown as beneficially owning 218,561 shares directly. The filing was signed by an attorney-in-fact on 08/08/2025.

P3 Health Partners Inc. reported a director-level equity award: Jeffrey G. Park was granted 2,000 restricted stock units (RSUs) under the company's 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock and the RSUs vest one year from the grant date. The grant was recorded as an acquisition at a $0 price and the filing shows 218,561 shares beneficially owned by the reporting person following the award, held in a direct form of ownership. This filing documents a routine equity-based compensation event for a director, specifying award mechanics and post-grant holdings.

P3 Health Partners Inc. (PIII) Form 4 summary: Director Leisure Lawrence B. was granted 2,000 restricted stock units (RSUs) on 08/06/2025 under the P3 Health Partners 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock and the RSUs vest one year from the grant date. The grant was recorded at a $0 price. Following the reported transaction, the reporting person beneficially owned 218,561 Class A shares. The Form 4 lists the reporting person as a director and was signed by an attorney-in-fact on 08/08/2025.

P3 Health Partners Inc. Director Thomas Edmunds Price was granted 2,000 restricted stock units (RSUs) on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the award vests one year from the grant date, meaning delivery of shares occurs only after vesting. The grant was made under the company’s 2021 Incentive Award Plan and shows an acquisition at no cash price.

After the grant, the filing reports 218,561 shares beneficially owned by the reporting person on a direct basis. This transaction is a typical equity-based compensation award to a director and does not reflect an immediate sale or transfer of issued shares.